Our findings demonstrated that taraxerone markedly inhibited the increase in ROS and MDA levels in both sepsis-induced ALI mice and LPS-induced primary macrophages, whereas SOD activity and GSH levels were prominently increased by taraxerone treatment. The gene discussed is SOD1; the disease is Sepsis.